Gastroesophageal Cancer – Unmet Need – Unmet Need – Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (US/EU)
Approximately 40% of gastric and gastroesophageal junction (GEJ) adenocarcinoma patients present with metastasis, and half of patients with localized disease progress to metastatic disease. Patients generally present with a variety of actionable mutations, creating substantial market opportunity for treatments. Current options for metastatic gastric and GEJ adenocarcinoma are limited; chemotherapy agents are still the backbone of therapy, and targeted agents such as Keytruda are limited to specific subtypes. Thus, a strong need remains for drugs that improve patients’ overall survival and are less toxic. Effective drugs for HER2-negative disease are similarly needed.
QUESTIONS ANSWERED
- Which attributes most influence prescribers’ decisions for metastatic gastric and gastroesophageal adenocarcinoma?
- How do current therapies such as VEGFR2 and HER2 inhibitors perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunity in the treatment of metastatic gastric and gastroesophageal adenocarcinoma?
- What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for HER2-negative metastatic gastric and gastroesophageal adenocarcinoma?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in December 2023
Key companies: Eli Lilly, Daiichi Sankyo, Taiho Oncology, BMS, Merck
Key drugs: Cyramza, Enhertu, Lonsurf, Opdivo, Keytruda
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
KEY FEATURE
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
